-+ 0.00%
-+ 0.00%
-+ 0.00%

A late Novartis trial for muscle disease failed, and some of the drug research companies' stock prices fell before the market. SAREPTA THERAPEUTICS fell 15.6% and DYNE THERAPEUTICS declined 29%.

Zhitongcaijing·09/08/2026 10:17:04
Listen to the news
A late Novartis trial for muscle disease failed, and some of the drug research companies' stock prices fell before the market. SAREPTA THERAPEUTICS fell 15.6% and DYNE THERAPEUTICS declined 29%.